Hospital Son Llatzer
- Address
- lock Available on a paid plan
Cardiovascular Diseases and Inherited Heart Conditions
At Hospital Son Llatzer in Palma, clinical research in cardiology focuses on cardiovascular disease and congenital, hereditary, and neonatal disorders, with particular attention to people at risk of developing dilated cardiomyopathy. The studies are designed to explore whether earlier treatment can help protect heart function and reduce the chance of structural changes before symptoms appear.
- Genetic carriers of dilated cardiomyopathy-causing variants
- Preventing decline in heart pumping function and ventricular enlargement
- Evaluating early therapy to delay or reduce disease expression
These trials aim to improve prevention and long-term monitoring for individuals with inherited heart risk.
Hypertrophic Cardiomyopathy and Exercise Capacity
Research at this site also examines symptomatic obstructive hypertrophic cardiomyopathy, a condition that can limit daily activity and cause significant heart-related symptoms. The clinical trials are comparing treatment options to better understand how to improve exercise tolerance and overall symptom control in affected adults.
- Symptomatic obstructive hypertrophic cardiomyopathy
- Improving exercise capacity and symptom management
- Comparing a newer heart therapy with standard treatment
The goal is to find approaches that may offer better functional outcomes for people living with this form of cardiomyopathy.
Neoplasms and Lung Cancer
Clinical trial activity at Hospital Son Llatzer includes research in neoplasms, especially metastatic non-small cell lung cancer. These studies are testing whether new treatment combinations can improve outcomes for patients whose disease has spread and whose tumors show low PD-L1 expression.
- Metastatic non-small cell lung cancer
- Assessing treatment effectiveness in advanced cancer
- Exploring whether new combinations can extend survival and delay progression
This work supports the search for more effective options in advanced lung cancer care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 152 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 140 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 34 by active trials.
- 1Fundacion GECP4active
lock +33 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fundacion GECP7trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Son Llatzer
lock Showing 1 of 95 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 152 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 12 | Unknown | 2018-04-04 | 2025-07-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.